XML 35 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Balance Sheets (USD $)
Sep. 30, 2014
Dec. 31, 2013
Current assets:    
Cash and cash equivalents $ 70,669,000 $ 33,719,796
Short-term investments 30,259,285 18,905,608
Accounts receivable 1,621,994 3,301,563
Prepaid expenses and other current assets 542,006 637,433
Prepaid expenses and other current assets from affiliated entity 1,482,487 2,057,350
Deferred tax asset 61,839 61,839
Total current assets 104,636,611 58,683,589
Restricted cash 0 100,762
Fixed assets, net 4,634,058 2,886,545
Investment in affiliated entity 8,998,375 9,664,587
Intangible assets, net 5,006,658 5,718,778
Goodwill 10,113,371 [1] 10,113,371 [1]
Common stock warrants 591,000 717,500
Other assets 552,459 402,075
Total assets 134,532,532 88,287,207
Current liabilities:    
Accounts payable and accrued expenses 4,698,161 5,444,508
Accounts payable and accrued expenses due to affiliated entity 94,250 522,255
Accrued clinical trial expenses 1,259,690 1,446,180
Common stock warrants 2,207,388 19,540,583
Deferred revenue 254,542 1,624,388
Deferred revenue from affiliated entity 413,541 388,542
Total current liabilities 8,927,572 28,966,456
Deferred revenue, net of current portion 2,898,775 1,997,333
Deferred revenue from affiliated entity, net of current portion 930,444 1,211,694
Deferred rent 4,535,722 3,013,263
Deferred tax liabilities 195,778 195,778
Total liabilities 17,488,291 35,384,524
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Common stock 60,458 52,577
Additional paid-in capital 441,281,144 348,267,389
Accumulated deficit (324,498,886) (295,788,577)
Accumulated other comprehensive loss (110,176) (76,365)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 116,732,540 52,455,024
Non-controlling interest 311,701 447,659
Total stockholders’ equity 117,044,241 52,902,683
Total liabilities and stockholders’ equity $ 134,532,532 $ 88,287,207
[1] Goodwill was recorded from the Inovio AS acquisition in January 2005 and from the acquisition of VGX in June 2009 for $3.9 million and $6.2 million, respectively.